Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123019422 | 12301942 | 2 | F | 2001 | 20160613 | 20160425 | 20160913 | PER | US-ASTRAZENECA-2012BM12432 | ASTRAZENECA | 58.00 | YR | M | Y | 81.60000 | KG | 20160913 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123019422 | 12301942 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | SINGLE DOSE TRAY, 2 MG ONCE A WEEK | 22200 | ||||||||||
| 123019422 | 12301942 | 2 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | PEN, 2 MG ONCE A WEEK | 72840 | 22200 | |||||||||
| 123019422 | 12301942 | 3 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | PEN, 2 MG ONCE A WEEK | 22200 | ||||||||||
| 123019422 | 12301942 | 4 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | 29220 | UG | Y | U | 0 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | |||
| 123019422 | 12301942 | 5 | SS | ZESTRIL | LISINOPRIL | 1 | Oral | 0 | 10 | MG | TABLET | QD | |||||||
| 123019422 | 12301942 | 6 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 1000 | MG | QD | ||||||||
| 123019422 | 12301942 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 1000 | MG | BID | ||||||||
| 123019422 | 12301942 | 8 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123019422 | 12301942 | 1 | Type 2 diabetes mellitus |
| 123019422 | 12301942 | 2 | Type 2 diabetes mellitus |
| 123019422 | 12301942 | 3 | Type 2 diabetes mellitus |
| 123019422 | 12301942 | 4 | Type 2 diabetes mellitus |
| 123019422 | 12301942 | 5 | Hypertension |
| 123019422 | 12301942 | 6 | Type 2 diabetes mellitus |
| 123019422 | 12301942 | 7 | Type 2 diabetes mellitus |
| 123019422 | 12301942 | 8 | Blood cholesterol abnormal |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123019422 | 12301942 | Decreased appetite | |
| 123019422 | 12301942 | Glycosylated haemoglobin decreased | |
| 123019422 | 12301942 | Injection site bruising | |
| 123019422 | 12301942 | Injection site nodule | |
| 123019422 | 12301942 | Type 2 diabetes mellitus | |
| 123019422 | 12301942 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123019422 | 12301942 | 2 | 201206 | 0 | ||
| 123019422 | 12301942 | 3 | 2014 | 0 | ||
| 123019422 | 12301942 | 4 | 200608 | 2014 | 0 | |
| 123019422 | 12301942 | 7 | 200109 | 0 |